Physician profile
Ravi Gupta
NPI 1235795295
$1,493.14
in general payments reported to CMS, 2019-2025
20 companies · $519 in 2025
The $519 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $346 · 2024: $628 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.75 |
| Education | $215.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $186.98 | 2023-2024 | |
| Incyte Corporation | $179.40 | 2023 | Jakafi |
| Merck Sharp & Dohme LLC | $175.36 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Lilly USA, LLC | $170.13 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $147.85 | 2024-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $106.66 | 2024-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $101.45 | 2024 | |
| Celgene Corporation | $66.41 | 2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $56.05 | 2024 | Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $50.22 | 2024-2025 | Libtayo, Lynozyfic |
| Eisai INC. | $43.96 | 2025 | |
| Glaxosmithkline, LLC. | $38.76 | 2025 | Jemperli, Zejula |
| Amneal Pharmaceuticals LLC | $28.42 | 2024 | Avastin, Neupogen, Neulasta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.75 | 2025 | |
| Mirati Therapeutics, INC. | $24.00 | 2024 | Krazati |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $20.92 | 2023 | |
| Novocure INC. | $20.01 | 2025 | Optune Lua (Novottf-200t) |
| Puma Biotechnology, INC. | $20.00 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.59 | 2025 | |
| Exelixis INC. | $13.22 | 2024 | Cabometyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.